Alexis Desieno Sells 7,324 Shares of Cardlytics, Inc. (NASDAQ:CDLX) Stock

Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) CFO Alexis Desieno sold 7,324 shares of the company's stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $1.78, for a total value of $13,036.72. Following the transaction, the chief financial officer directly owned 171,858 shares in the company, valued at $305,907.24. This represents a 4.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Cardlytics Trading Up 3.6%

CDLX traded up $0.07 during trading on Thursday, hitting $1.87. 719,705 shares of the stock traded hands, compared to its average volume of 997,936. The firm has a 50-day moving average of $1.80 and a 200 day moving average of $2.40. Cardlytics, Inc. has a 12-month low of $1.22 and a 12-month high of $9.48. The firm has a market capitalization of $97.91 million, a P/E ratio of -0.52 and a beta of 1.21. The company has a debt-to-equity ratio of 2.62, a current ratio of 1.19 and a quick ratio of 1.19.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Cardlytics in a report on Thursday, March 13th. Evercore ISI dropped their price objective on Cardlytics from $4.00 to $3.00 and set an "in-line" rating for the company in a research note on Thursday, March 13th. Finally, Lake Street Capital reduced their target price on Cardlytics from $3.00 to $2.50 and set a "hold" rating for the company in a research report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $3.50.

Institutional Investors Weigh In On Cardlytics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its position in shares of Cardlytics by 3.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 402,552 shares of the company's stock worth $1,493,000 after purchasing an additional 12,209 shares in the last quarter. Brooktree Capital Management raised its holdings in Cardlytics by 4.5% in the 4th quarter. Brooktree Capital Management now owns 175,210 shares of the company's stock worth $650,000 after acquiring an additional 7,568 shares during the last quarter. Intech Investment Management LLC boosted its stake in Cardlytics by 31.3% during the 4th quarter. Intech Investment Management LLC now owns 19,310 shares of the company's stock valued at $72,000 after purchasing an additional 4,607 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Cardlytics in the fourth quarter worth $62,000. Finally, Geode Capital Management LLC boosted its position in shares of Cardlytics by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 1,060,739 shares of the company's stock valued at $3,936,000 after buying an additional 7,561 shares during the last quarter. 68.10% of the stock is owned by hedge funds and other institutional investors.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.